ArticleBone marrow transplantation2026
Sequential CLAGE-Ven (cladribine, cytarabine, etoposide, and venetoclax) with reduced-intensity conditioning improves outcomes in patients with refractory acute myeloid leukemia: a prospective phase II study.
Wen-Hui Gao, Chu-Ran Wang, Li-Ning Wang, Ming Wan, Jie-Ling Jiang, Didier Blaise, Jiong Hu, Ling Wang
Abstract readLetter
In one paragraphArticle in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Wen-Hui Gao *Shanghai Institute of Hematology, Bone Marrow & Blood Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chu-Ran Wang *Shanghai Institute of Hematology, Bone Marrow & Blood Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li-Ning WangShanghai Institute of Hematology, Bone Marrow & Blood Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ming WanShanghai Clinical Research Center (SCRC), Feng Lin International Centre, Shanghai, China.
Jie-Ling JiangShanghai Institute of Hematology, Bone Marrow & Blood Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiong HuShanghai Institute of Hematology, Bone Marrow & Blood Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. hj10709@rjh.com.cn.ORCID http://orcid.org/0000-0002-5613-1195 Ling WangShanghai Institute of Hematology, Bone Marrow & Blood Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. wl11406@rjh.com.cn.ORCID http://orcid.org/0000-0001-7965-686X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
What OpenQuestion holds
Textmetadata
Read underepoch 390